Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02315768 · ClinicalTrials.gov registry record · Phase 1
Ibrutinib in Combination With GA101 (Obinutuzumab) in Previously Untreated Chronic Lymphocytic Leukemia (CLL) Patients.
A Phase 1 study, sponsored by University of California, San Diego.
- Completed
- Registry status
- Phase 1
- Development phase
- 32
- Enrollment target
NCT02315768 is a Phase 1 study that has completed, run by University of California, San Diego. The registered enrollment target is 32 participants.
The verdict
NCT02315768, a Phase 1 study, has completed, sponsored by University of California, San Diego.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 32 participants
- Enrollment target
Study Summary
The purpose of the study is to determine whether ibrutinib in combination with GA101 - Obinutuzumab might be useful for the treatment of CLL. This study will evaluate if ibrutinib in combination with GA101 - Obinutuzumab can reduce the amount of cancerous cells in body.
Interventions
- DRUG Ibrutinib
- DRUG GA101
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 32 participants |
| Start Date | 2015-08-26 |
| Est. Completion | 2022-04-18 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02315768
The ClinicalTrials.gov registry entry for NCT02315768 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 32 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is University of California, San Diego, which has 775 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Ibrutinib is the first listed.
NCT02315768 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT02315768 about?
NCT02315768 is a clinical study titled "Ibrutinib in Combination With GA101 (Obinutuzumab) in Previously Untreated Chronic Lymphocytic Leukemia (CLL) Patients.". The purpose of the study is to determine whether ibrutinib in combination with GA101 - Obinutuzumab might be useful for the treatment of CLL. This study will evaluate if ibrutinib in combination with GA101 - Obinutuzumab can reduce the amount of cancerous cells in body.
What is the current status of trial NCT02315768?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 32 participants. The study started on 2015-08-26. Estimated completion is 2022-04-18.
What interventions are being tested in trial NCT02315768?
The interventions under investigation include: Ibrutinib (DRUG), GA101 (DRUG).
Who is sponsoring clinical trial NCT02315768?
This trial is sponsored by University of California, San Diego, which has 775 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.